Breaking News Instant updates and real-time market news.

AKTS

Akoustis

$8.86

0.66 (8.05%)

, AMRC

Ameresco

$15.15

-0.28 (-1.81%)

08:43
05/14/19
05/14
08:43
05/14/19
08:43

Oppenheimer to hold a conference

4th Annual Emerging Growth Conference will be held in New York on May 14.

AKTS

Akoustis

$8.86

0.66 (8.05%)

AMRC

Ameresco

$15.15

-0.28 (-1.81%)

APPS

Digital Turbine

$3.76

-0.07 (-1.83%)

EGAN

eGain

$8.13

-0.065 (-0.79%)

OSS

One Stop Systems

$2.12

-0.06 (-2.75%)

OPRX

OptimizeRx

$13.39

-0.14 (-1.03%)

MVIS

MicroVision

$0.87

-0.0255 (-2.85%)

MTBC

MTBC, Inc

$4.99

-0.1 (-1.96%)

MITK

Mitek Systems

$10.35

-0.28 (-2.63%)

LMNR

Limoneira

$21.99

-1 (-4.35%)

EVER

EverQuote

$11.22

0.5 (4.66%)

RBBN

Ribbon Communications

$4.75

-0.08 (-1.66%)

INVE

Identiv

$5.10

(0.00%)

NP

Neenah Paper

$60.15

-2.17 (-3.48%)

RESN

Resonant

$3.05

-0.11 (-3.48%)

CPST

Capstone Turbine

$0.76

-0.0384 (-4.82%)

OPY

Oppenheimer Holdings

$25.39

-0.92 (-3.50%)

SSTI

ShotSpotter

$43.58

-0.93 (-2.09%)

QUIK

QuickLogic

$0.81

-0.0354 (-4.17%)

DZSI

Dasan Zhone

$11.64

-0.76 (-6.13%)

  • 14

    May

  • 15

    May

  • 16

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 28

    May

  • 28

    May

  • 29

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 10

    Jun

  • 11

    Jun

  • 11

    Jun

  • 11

    Jun

  • 13

    Jun

  • 13

    Jun

  • 24

    Jun

  • 25

    Jun

  • 13

    Nov

AKTS Akoustis
$8.86

0.66 (8.05%)

02/05/19
NORL
02/05/19
DOWNGRADE
NORL
Market Perform
Akoustis downgraded to Market Perform from Outperform at Northland
12/18/18
CHLM
12/18/18
INITIATION
Target $8
CHLM
Buy
Akoustis initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Anthony Stoss started Akoustis (AKTS) with a Buy rating and $8 price target. The analyst notes that the company sits in a "unique position" with BAW filters designed with a proprietary single crystal structure. Its filters offer superior performance at higher frequencies than the two dominant players - Broadcom (AVGO) and Qorvo (QRVO) - as they can handle higher power, have better acoustic performance, transfer heat out much faster, and are 23-times smaller. Stoss believes these characteristics will allow Akoustis to penetrate three enormous markets in a meaningful way.
05/13/19
CHLM
05/13/19
NO CHANGE
Target $12
CHLM
Buy
Akoustis price target raised to $12 from $10 at Craig-Hallum
Craig-Hallum analyst Anthony Stoss raised his price target for Akoustis Technologies to $12 from $10 after the company announced that it received its first purchase order from a multi-billion dollar tier-1 wireless telecommunications company to develop 5 GHz BAW filters for mobile handsets. Akoustis is also now in talks with multiple tier-1 handset manufacturers for their filter solutions, Stoss tells investors in a research note. He believes the company is seeing heavy customer interest and reiterates a Buy rating on the shares.
05/13/19
OPCO
05/13/19
NO CHANGE
Target $10
OPCO
Outperform
Akoustis top line to continue accelerating, says Oppenheimer
Oppenheimer analyst Rick Schafer kept his Outperform rating and $10 price target on Akoustis after its Q3 results, saying that earnings were short of consensus, but some of the company's military sales had been pushed out to Q4. The analyst notes that investor focus falls on the company's handset market, which is Akoustis' "top volume opportunity," and expects its top line to accelerate as Akoustis translates order wins into revenues.
AMRC Ameresco
$15.15

-0.28 (-1.81%)

03/13/19
RILY
03/13/19
INITIATION
Target $19
RILY
Buy
Ameresco resumed with a Buy at B. Riley FBR
B. Riley FBR analyst Christopher Van Horn resumed coverage of Ameresco with a Buy rating and $19 price target. The rating and price target are unchanged from the firm's prior coverage.
03/07/19
ADAM
03/07/19
NO CHANGE
Target $20
ADAM
Buy
Ameresco price target raised to $19.50 from $16.50 at Canaccord
Canaccord analyst Chip Moore raised his price target on Ameresco to $19.50 from $16.50 following solid Q4 results. The analyst cited its fully contracted back log which provides good visibility, the continued acceleration of its asset portfolio, and what he sees as an attractive risk/reward. Moore reiterated his Buy rating on Ameresco shares.
12/19/18
RILY
12/19/18
INITIATION
Target $17.5
RILY
Buy
Ameresco initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Carter Driscoll started Ameresco with a Buy rating and $17.50 price target. The company's recurring revenue and backlog make it a "defensive play on efficiency," Driscoll tells investors in a research note.
03/04/19
ROTH
03/04/19
UPGRADE
Target $19
ROTH
Buy
Ameresco upgraded to Buy from Neutral at Roth Capital
Roth Capital analyst Craig Irwin upgraded Ameresco to Buy from Neutral as he expects the company to report "strong" Q4 results, supported by rising ESPC project activity and continued strengthening of the EBITDA contribution from the Canton-GNG plant. Looking forward, the Phoenix-GNG plant should drive a $15M step up in 2019 EBITDA, in addition to the tail from the 2018 Canton ramp, pointing to good potential for execution well above consensus, he contends. Irwin also raised his price target on the shares to $19 from $16.
APPS Digital Turbine
$3.76

-0.07 (-1.83%)

01/03/19
ROTH
01/03/19
NO CHANGE
Target $3
ROTH
Buy
Apple weakness could spill over into Digital Turbine, says Roth Capital
Roth Capital analyst Darren Aftahi says weakness from Apple's (AAPL) negative pre-announcement, citing primarily emerging market weakness and fewer iPhone upgrades, could spill over into Digital Turbine (APPS). The analyst would be a buyer on any material weakness given Digital Turbine has no handset exposure to China and its exposure is to the Android based platform, where handsets tend to skew lower on ASP, in general. Apple weakness could create buying opportunity, he contends. Aftahi reiterates a Buy rating and $3 price target on Digital Turbine's shares.
02/26/19
RILY
02/26/19
NO CHANGE
Target $4
RILY
Buy
Digital Turbine price target raised to $4 from $2.90 at B. Riley FBR
B. Riley FBR analyst Sameet Sinha raised his price target for Digital Turbine to $4 saying the company's domestic revenue-per-device has four-times appreciation potential. The analyst keeps a Buy rating on the shares.
03/26/19
RILY
03/26/19
NO CHANGE
Target $4
RILY
Buy
Digital Turbine selloff yesterday a buying opportunity, says B. Riley FBR
B. Riley FBR analyst Sameet Sinha views the selloff yesterday in shares of Digital Turbine (APPS) on Google's (GOOG, GOOGL) potential changes to Chrome as a buying opportunity. The analyst believes the changes should have a minimal impact on Digital Turbine and keeps a Buy rating on the shares with a $4 price target. The stock closed yesterday down 14% to $3.09.
03/27/19
ROTH
03/27/19
NO CHANGE
Target $4.25
ROTH
Buy
Digital Turbine selloff creates buying opportunity, says Roth Capital
Roth Capital analyst Darren Aftahi believes Digital Turbine's (APPS) shares were weak on chatter about changes Google (GOOG; GOOGL) could make to its Chrome browser and third-party ad-targeting restrictions. The analyst argues that the company was lumped into this basket, when in fact about 85% of its revenue still comes from dynamic pre-load with the remaining 15% from new services, which to his knowledge have little if most likely any exposure to Google. Aftahi would be "accumulating on unnecessary weakness." He reiterates a Buy rating and a $4.25 price target on Digital Turbine's shares.
EGAN eGain
$8.13

-0.065 (-0.79%)

09/07/18
ROTH
09/07/18
NO CHANGE
Target $16
ROTH
Buy
eGain FY19 guidance looks conservative, says Roth Capital
Roth Capital analyst Richard Baldry noted that eGain's initial FY19 guidance was moderately below his forecast, but he also believes that it appears conservative as he sees the company being positioned to at least grow SaaS revenues on par with FY18, and perhaps better. He reiterates a Buy rating and $16 price target on eGain shares.
05/09/19
CHLM
05/09/19
DOWNGRADE
CHLM
Hold
eGain downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Jeff Van Rhee downgraded eGain to Hold from Buy following the company's Q3 earnings report.
05/09/19
05/09/19
DOWNGRADE
Target $10

Hold
eGain downgraded to Hold after quarterly results at Craig-Hallum
As previously reported, Craig-Hallum analyst Jeff Van Rhee downgraded eGain to Hold from Buy following quarterly results as he awaits a more attractive risk/reward profile. The analyst has increased concerns around churn and the attractiveness of the platform to new customers. He also lowered his price target on the shares to $10 from $12.
07/18/18
NEED
07/18/18
INITIATION
Target $16
NEED
Buy
eGain initiated with a Buy at Needham
Needham analyst Ryan MacDonald imitated eGain with a Buy and $16 price target saying it is a leading provider of cloud-based customer engagement software and expects a re-acceleration of revenue growth and margin expansion in FY19 and FY20, which justifies a premium valuation.
OSS One Stop Systems
$2.12

-0.06 (-2.75%)

04/04/19
NBLE
04/04/19
INITIATION
Target $4
NBLE
Outperform
One Stop Systems initiated with an Outperform at Noble Capital
Noble Capital analyst Joe Gomes initiated One Stop Systems with an Outperform and $4 price target Gomes said One Stop Systems is a leader in the High Performance Computing space with particular emphasis on the "AI on the Fly" and the migration to PCI Express Gen 4 spaces through the design and manufacture of custom servers, compute accelerators, solid-state storage arrays, and system expansion systems. The analyst sees multiple avenues of growth from a ramp-up of existing OEM and military design wins, winning new OEM and military design awards, and an ongoing acquisition program to expand the depth of the company's offerings.
OPRX OptimizeRx
$13.39

-0.14 (-1.03%)

01/03/19
WBLR
01/03/19
INITIATION
WBLR
Outperform
OptimizeRx well positioned for 'industry mega trends,' says William Blair
William Blair analyst Ryan Daniels initiated coverage of OptimizeRx with an Outperform rating. The analyst laid out six primary reasons for why he views OptimizeRx shares as an attractive small-cap healthcare technology holding. OptimizeRx's solutions address a critical, but largely unmet need for both pharmaceutical companies and physicians, Daniels tells investors in a research note. Further, he believes it is well positioned to benefit from "several industry mega trends" that will drive organic growth.
01/03/19
01/03/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cision (CISN) initiated with a Neutral at Goldman Sachs. 2. Cheniere Energy (LNG) initiated with a Buy at UBS. 3. OptimizeRx (OPRX) initiated with an Outperform at William Blair. 4. Comerica (CMA) initiated with a Buy at Argus. 5. Kirkland Lake Gold (KL) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/03/19
WBLR
01/03/19
INITIATION
WBLR
Outperform
OptimizeRx initiated with an Outperform at William Blair
William Blair analyst Ryan Daniels started OptimizeRx with an Outperform rating.
11/06/18
ROTH
11/06/18
NO CHANGE
Target $30
ROTH
Buy
OptimizeRx price target raised to $30 from $25 at Roth Capital
Roth Capital analyst Richard Baldry lowered his price target for OptimizeRx to $30 from $25 on "impressive" Q3 results, with 75% organic growth supporting record revenues, a second quarter of GAAP profitability, growing pro forma EPS and 28% adjusted operating margins. The analyst reiterates a Buy rating on the shares.
MVIS MicroVision
$0.87

-0.0255 (-2.85%)

12/19/18
CHLM
12/19/18
INITIATION
Target $1.75
CHLM
Buy
MicroVision initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Mike Malouf started MicroVision with a Buy rating and $1.75 price target. The analyst's optimistic case scenario assumes the smart Smart Speaker market grows to 100M units over the next few years, with 6.5M units incorporating the company's display-only capability and 3M integrating its interactive display functionality. Including other verticals, Malouf believes the company could generate $300M in revenue and over $50M in EBITDA, which at 8 times results in a $3.50 stock, or a 500% return.
MTBC MTBC, Inc
$4.99

-0.1 (-1.96%)

01/23/19
HCWC
01/23/19
NO CHANGE
Target $6
HCWC
Buy
Medical Transcription Billing called a 'top choice' for 2019 at H.C. Wainwright
H.C. Wainwright analyst Kevin Dede says Medical Transcription Billing is "woefully under-appreciated and worthy of an aggressive call to attention for small cap investors despite the currently volatile market environment." He thinks the stock has the potential to be one of the best performers in his coverage universe this year and reiterates a Buy rating on the name with a $6 price target.
03/15/19
DOTC
03/15/19
INITIATION
Target $7.5
DOTC
Buy
MTBC, Inc initiated with a Buy at Dougherty
Dougherty analyst Gene Mannheimer initiated MTBC, Inc with a Buy and $7.50 price target.
MITK Mitek Systems
$10.35

-0.28 (-2.63%)

03/26/19
BNCH
03/26/19
NO CHANGE
Target $15
BNCH
Buy
Mitek Systems recent strength due to takeover speculation, says Benchmark
Benchmark analyst Mark Schappel attributed the fact that Mitek Systems shares advanced more than 6.5% yesterday and are up 9% during the past week to takeover speculation, stating that some investors may believe that an announcement around a potential deal could be near. He raised his price target on Mitek shares to $15 from $12 to account for multiple expansion in the broader software sector and keeps a Buy rating on the stock.
03/29/19
BNCH
03/29/19
NO CHANGE
Target $15
BNCH
Buy
Mitek Systems takeover price of $20 'not out of the question,' says Benchmark
Benchmark analyst Mark Schappel said his $15 price target on Mitek Systems "may be one of the more aggressive ones on the Street," but based on recent transactions in the space he believes it is on the conservative side. In a takeover scenario, Schappel thinks Mitek could fetch up to $18.50 per share and does not think $20 per share "is out of the question," he tells investors. In a previous note to investors, Schappel attributed recent strength in Mitek Systems shares to takeover speculation, the Fly notes. The analyst keeps a Buy rating and $15 price target on Mitek shares.
05/02/19
BNCH
05/02/19
NO CHANGE
Target $14
BNCH
Buy
Mitek Systems' good results overshadowed by rejected bids, says Benchmark
Benchmark analyst Mark Schappel said Mitek Systems reported good Q2 results, but this is being overshadowed by the announcement that the company rejected all outstanding buyout offers and concluded its strategic review process. While not surprised to see the stock trade down in afterhours following the news, he thinks "a few more quarters of consistent execution" can get the stock trading up to the 5x revenue range and Schappel keeps a Buy rating on Mitek, which he believes should start trading on fundamentals. He trimmed his price target on Mitek to $14 from $15.
12/27/18
BNCH
12/27/18
NO CHANGE
Target $12
BNCH
Buy
Benchmark says Mitek could be worth $12-$13 per share in 'normal' environment
After Mitek Systems disclosed that it has received expressions of interest from multiple parties and that activist hedge fund Elliott Management has withdrawn its nomination of a dissident slate of directors since the company is evaluating its options, including a possible sale or merger, Benchmark analyst Mark W. Schappel said his "long held" view has been that Mitek could be worth $12-$13 per share "in a more normal operating environment." The analyst, who said that the news and Elliott's $11.50 outstanding bid "suggests that our inclinations are largely correct," keeps a Buy rating on Mitek shares with a $12 price target.
LMNR Limoneira
$21.99

-1 (-4.35%)

01/08/19
SPHN
01/08/19
INITIATION
Target $24
SPHN
Overweight
Limoneira initiated with an Overweight at Stephens
Stephens analyst Ben Bienvenu initiated coverage of Limoneira with an Overweight rating and $24 price target, stating that it has a unique position and portfolio of assets along with a "compelling" long-term growth story. He sees Limoneira's earnings approaching an inflection point that he expects to begin in FY19, Bienvenu added.
09/11/18
LSCM
09/11/18
NO CHANGE
Target $31
LSCM
Buy
Limoneira shares will likely sell off today, says Lake Street
Lake Street analyst Chris Krueger expects shares of Limoneira to sell off today following last night's earnings shortfall on weather. The stock had risen 65% since February and was pricing in expectations of a Q3 beat and guidance increase, neither of which happened, Krueger tells investors in a post-earnings research note. While sales beat estimates, poor weather hurt margins and caused an earnings miss, the analyst explains. However, he remains confident Limoneira will continue to grow its core agribusiness and generate additional cash flow from its real estate and water rights. Krueger raised his price target for the shares to $31 from $30 and keeps Buy rating on the name.
09/11/18
BUCK
09/11/18
NO CHANGE
Target $32
BUCK
Buy
Limoneira positioned for another year of growth, says Buckingham
Buckingham analyst Eric Larson raised his price target for Limoneira to $32 from $30, while reiterating a Buy rating on the shares. The analyst believes Limoneira is still positioned for another year of growth in FY18 behind a new efficient lemon packing plant, increased lemon volumes, additional lemon acreage, and a solid return to profitability in oranges. Further, additional runway for growth in FY19 is now being supported by two accretive acquisitions, he adds.
05/14/19
SPHN
05/14/19
DOWNGRADE
Target $18
SPHN
Equal Weight
Limoneira downgraded to Equal Weight from Overweight at Stephens
Stephens analyst Ben Bienvenu downgraded Limoneira to Equal Weight from Overweight and lowered his price target for the shares to $18 from $25. While the company lowered its full year guidance, second half of 2019 expectations remain too aggressive to totally eliminate the risk of another guidance reduction later in the year, Bienvenu tells investors in a research note. The analyst expects Limoneira shares to trade off today given the magnitude of the Q2 miss and lack of visibility into the remainder of fiscal 2019.
EVER EverQuote
$11.22

0.5 (4.66%)

04/04/19
JMPS
04/04/19
NO CHANGE
Target $12
JMPS
Outperform
EverQuote price target lowered to $12 from $18 at JMP Securities
JMP Securities analyst Ronald Josey said he believes that EverQuote is making progress in growing consumer demand, adding more carriers, improving carrier integrations and launching newer verticals and that progress in its core demand channels seen in Q4 has continued thus far in Q1. However, given increasing investments in marketing and advertising in 2019 and beyond, he lowered his price target on EverQuote shares to $12 from $18. Josey keeps an Outperform rating on the stock.
05/07/19
JPMS
05/07/19
NO CHANGE
Target $14
JPMS
Overweight
EverQuote price target raised to $14 from $12 at JPMorgan
JPMorgan analyst Doug Anmuth raised his price target for EverQuote to $14 from $12 saying the company's Q1 results were "solidly above expectations across the board." This was a "clean" beat and raise quarter and the newly announced health insurance vertical is a positive surprise, Anmuth tells investors in a research note. He keeps an Overweight rating on EverQuote shares.
02/26/19
02/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exact Sciences (EXAS) upgraded to Buy from Neutral at Goldman Sachs by analyst Patrick Donnelly, who said the current momentum of the Cologuard commercial ramp provides "strong basis" for the company's premium valuation while the combination of positive Cologuard catalysts and new product roll-outs provide upside to current levels, even after the stock's 75% rally since the beginning of 2018. Exact Sciences is a "must-own growth stock" given the "clean runway forward that is largely in its control with potential for discovery value in the pipeline outside of Cologuard," the analyst said. 2. Siemens (SIEGY) upgraded to Overweight from Neutral at JPMorgan by analyst Andreas Willi, who sees a relative valuation opportunity after the stock's 27% underperformance over the past two years. He believes investor sentiment can improve "after a period where the story has drifted." 3. Kadmon (KDMN) upgraded to Buy from Neutral at Citi by analyst Robyn Karnauskas, who assigned a 50% probability to KD-025 in chronic graft versus host disease with an unadjusted ~$900M market opportunity. However, upside to the stock will depend on quality of the data likely, Karnauskas said. 4. EverQuote (EVER) upgraded to Buy following Q4 beat at BofA/Merrill by analyst Mat Schindler, who said user growth has re-accelerated, supporting evidence of a turnaround, and thinks estimates are conservative and views the risk/reward as attractive. 5. Ally Financial (ALLY) upgraded to Buy from Hold at Sandler O'Neill by analyst Christopher Donat, who said he believes Ally's near-prime auto finance book is "meaningfully less risky" than Santander Consumer's (SC) book or the unsecured credit cards of Discover (DFS) and Capital One (COF), yet all four stocks trade at similar multiples. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/26/19
BOFA
02/26/19
UPGRADE
Target $10.5
BOFA
Buy
EverQuote upgraded to Buy following Q4 beat at BofA/Merrill
As previously reported, BofA/Merrill upgraded EverQuote to Buy from Neutral with a new $10.50 price target following the Q4 beat. Analyst Nat Schindler said user growth has re-accelerated, supporting evidence of a turnaround, and thinks estimates are conservative and views the risk/reward as attractive.
RBBN Ribbon Communications
$4.75

-0.08 (-1.66%)

08/01/18
COWN
08/01/18
UPGRADE
COWN
Market Perform
Ribbon Communications upgraded to Market Perform from Underperform at Cowen
INVE Identiv
$5.10

(0.00%)

05/01/19
05/01/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lyft (LYFT) initiated with a Buy at Tigress Financial. 2. Waste Management (WM) and Republic Services (RSG) were initiated with a Sector Perform at RBC Capital. 3. Identiv (INVE) initiated with an Outperform at Oppenheimer. 4. The Stars Group (TSG) initiated with an Equal Weight at Morgan Stanley. 5. Avid Technology (AVID) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/15/19
LSCM
04/15/19
NO CHANGE
Target $9
LSCM
Buy
Identiv pullback brings buying opportunity, says Lake Street
Lake Street analyst Jaeson Schmidt views the recent pullback in shares of Identiv as a buying opportunity. After meeting with management and seeing some product demos at the International Security Conference & Exposition West last week, the analyst feels confident Identiv remains on track to see sustained revenue growth and achieve profitability this year. While the stock is down 21% since reporting Q4 results in early March, Schmidt does not think there has been any deterioration in the company's fundamentals. He sees an attractive entry point at current levels and reiterates a Buy rating on Identiv with a $9 price target.
04/30/19
OPCO
04/30/19
INITIATION
Target $7
OPCO
Outperform
Identiv initiated with an Outperform at Oppenheimer
Oppenheimer analyst Andrew Uerkwitz initiated Identiv with an Outperform rating and a price target of $7, calling the company a "microcap gem" in a growing and evolving access control market. The analyst is positive on the company's 3-year run of optimizing the business around its "core competency" with new acquired technology to accelerate its transition to a full suite offering, and expects Identiv to gain market share while growing faster than its peers.
04/30/19
OPCO
04/30/19
INITIATION
OPCO
Outperform
Identiv initiated with an Outperform at Oppenheimer
NP Neenah Paper
$60.15

-2.17 (-3.48%)

02/13/19
DADA
02/13/19
NO CHANGE
Target $77
DADA
Neutral
Neenah Paper price target lowered to $77 from $88 at DA Davidson
DA Davidson analyst Steven Chercover lowered his price target on Neenah Paper to $77 and kept his Neutral rating, saying its "soft" Q4 results have completed a "challenging" 2018 as input cost inflation cut into the company's operating profits. The analyst notes that while the management is confident in generating positive pricing momentum in 2019, he expects that it will "take some time before EBITDA margins bounce back to the mid-teen levels posted in recent years."
RESN Resonant
$3.05

-0.11 (-3.48%)

06/21/18
LOOP
06/21/18
INITIATION
Target $11
LOOP
Buy
Resonant initiated with a Buy at Loop Capital
Loop Capital analyst Cody Acree initiated Resonant with a Buy rating and a price target of $11. The analyst cites the company's Infinite Synthesized Network platform technology - "a software-based, high-precision modeling approach that is able to produce real-world testable results in a completed design" which allows Resonant to eliminate design flaws in the software before wafer production begins. Acree believes that this approach will be much more "attractive to the market than the traditional method of running multiple physical iterations through a wafer fab".
11/14/18
LOOP
11/14/18
NO CHANGE
Target $7
LOOP
Buy
Resonant price target lowered to $7 from $11 at Loop Capital
Loop Capital analyst Cody Acree lowered his price target on Resonant to $7 to reflect the "valuation contractions across the chip industry" along with his revisions of its royalty revenue timeline driven by its customers' pushout of their expected handset launch into the first half of 2019. The analyst also keeps his Buy rating on the shares, stating that the steady progress made by Resonant in "growing its funnel of engagements" should yield a "material revenue ramp in 2019". Acree further contends that the company is "well positioned to become a material supplier of advanced filter designs targeting the China market".
09/21/18
HCWC
09/21/18
NO CHANGE
Target $8
HCWC
Buy
Resonant reaction to CFO change a buying opportunity, says H.C. Wainwright
H.C. Wainwright analyst Kevin Dede said that the exit of Mike Seifert from Resonant only weeks after he joined as the company's second-ever CFO on September 2 "may raise both red flags and hackles on the back of the neck," but he clearly does not agree with anyone suggesting that a worse case scenario is behind this morning's news. He attributes the company's hiring and subsequent loss of Siefert as being due to "poor due diligence and a seemingly rash decision," and notes that Jeff Killian, the company's original CFO now turned consultant, has returned to his old post until a committed replacement can be found. Dede, who would use the "knee jerk reaction" in the stock as an opportunity to enlarge an investment position, keeps a Buy rating and $8 price target on Resonant shares, which are down 5% to $4.15 in early trading.
08/10/18
LOOP
08/10/18
NO CHANGE
Target $11
LOOP
Buy
Loop Capital encouranged by Resonant development process
Loop Capital analyst Cody Acree kept his Buy rating and $11 price target on Resonant after its Q2 results despite the company's reduction of FY18 revenue growth target from mid-single-digit millions to low-single-digit millions. The analyst notes that the outlook change is mainly due to end-customer timing rather than the company's development delays, adding that he remains encouraged by Resonant's pace of progress.
CPST Capstone Turbine
$0.76

-0.0384 (-4.82%)

08/01/18
08/01/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Capstone Turbine (CPST) initiated with a Buy at Maxim. 2. Lilis Energy (LLEX) initiated with a Buy at Stifel. 3. SS&C (SSNC) assumed with an Overweight at JPMorgan. 4. Magnolia Oil & Gas (MGY) initiated with an Outperform at Imperial Capital. 5. Fate Therapeutics (FATE) initiated with a Buy at Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/01/18
MAXM
08/01/18
INITIATION
Target $2.5
MAXM
Buy
Capstone Turbine initiated with a Buy at Maxim
Maxim analyst James Jang initiated Capstone Turbine with a Buy rating and a price target of $2.50. The analyst notes that the company's market divsersification should support its revenue expansion trend as it builds sales momentum. Jang further states that the shale oil industry is a key driver for Capstone's growth as its microturbines allow for reduced operating costs for its customers.
12/31/18
HCWC
12/31/18
NO CHANGE
Target $2
HCWC
Buy
Capstone Turbine shares could rebound on 2019 catalysts, says H.C. Wainwright
H.C. Wainwright analyst Amit Dayal believes the 50% pullback in shares of Capstone Turbine since mid-July overlooks the company's revenue and margin drivers. There are "several catalysts in the story that support a healthy outlook for the company," Dayal tells investors in a research note. These include the recently launched Distributor Support System with $1.1M in funding, demand for lower cost remanufactured systems, expansion in Russia, Middle East, Africa and South America, Dayal writes. He maintains a Buy rating on Capstone Turbine with a $2.00 price target.
02/08/19
ROTH
02/08/19
DOWNGRADE
Target $0.9
ROTH
Neutral
Capstone Turbine downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Craig Irwin downgraded Capstone Turbine to Neutral from Buy after the company's Q3 revenue missed expectations, noting that its microturbine gross margins were negative again. The analyst, who now thinks material progress on microturbine gross margins "is looking increasingly unlikely," expects product margins excluding parts and spares to be a "source of continued disappointment," he tells investors in a post-earnings research note. Irwin lowered his price target on Capstone shares to 90c from $1.25.
OPY Oppenheimer Holdings
$25.39

-0.92 (-3.50%)

SSTI ShotSpotter
$43.58

-0.93 (-2.09%)

03/05/19
03/05/19
NO CHANGE

ShotSpotter files to sell an aggregate of 386k shares of common stock
JMP Securities is acting as the sole underwriter for the offering.
05/10/19
WBLR
05/10/19
NO CHANGE
WBLR
Outperform
ShotSpotter selloff brings good entry point, says William Blair
William Blair analyst Matthew Pfau believes today's post-earnings selloff in shares of ShotSpotter provides a good entry point. The analyst admits, however, that ShotSpotter shares will likely be in the penalty box for several quarters as management regains investor confidence. With that said, Pfau does not think the recent customer loss highlighted by management is indicative of a broader trend. Further, ShotSpotter is selling to cities and municipalities, and the red tape in getting deals approved can be substantial and create the potential for delays, adds the analyst. Pfau keeps an Outperform rating on ShotSpotter shares.
05/10/19
LSCM
05/10/19
NO CHANGE
Target $50
LSCM
Buy
ShotSpotter earnings selloff a buying opportunity, says Lake Street
Lake Street analyst Jaeson Schmidt recommends using the post-earnings selloff in shares of ShotSpotter as a buying opportunity. The greater than 20% selloff is less reflective of any significant change to ShotSpotter's growth opportunities and more illustrative of a stock that was up 42% quarter-to-date and "priced for perfection," Schmidt tells investors in a research note. He continues to believe ShotSpotter is positioned to drive meaningful top line growth and improving profitability going forward. The analyst lowered his price target for the shares to $50 from $55 and keeps a Buy rating on the name.
05/10/19
DOTC
05/10/19
DOWNGRADE
DOTC
Neutral
ShotSpotter downgraded to Neutral from Buy at Dougherty
Dougherty analyst Jeremy Hamblin downgraded ShotSpotter to Neutral from Buy without a price target following the company's Q1 results.
QUIK QuickLogic
$0.81

-0.0354 (-4.17%)

08/08/18
08/08/18
NO CHANGE

QuickLogic reports Q2 EPS (4c), consensus (4c)
Reports Q2 revenue $3.1M, consensus $3.1M.
DZSI Dasan Zhone
$11.64

-0.76 (-6.13%)

TODAY'S FREE FLY STORIES

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

, GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

07:20
05/25/19
05/25
07:20
05/25/19
07:20
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

AMBA

Ambarella

$38.28

1.07 (2.88%)

ON

ON Semiconductor

$17.68

-0.235 (-1.31%)

NKE

Nike

$82.12

-0.51 (-0.62%)

ADDYY

Adidas

$0.00

(0.00%)

UAA

Under Armour

$23.54

0.075 (0.32%)

UA

Under Armour

$20.91

0.08 (0.38%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

VMC

Vulcan Materials

$126.28

1.25 (1.00%)

FLR

Fluor

$29.04

0.18 (0.62%)

ACM

Aecom

$31.56

-0.03 (-0.09%)

X

U.S. Steel

$13.63

-0.08 (-0.58%)

AKS

AK Steel

$2.00

-0.155 (-7.21%)

NUE

Nucor

$51.12

-0.27 (-0.53%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$12.85

0.11 (0.86%)

F

Ford

$9.83

-0.02 (-0.20%)

GM

General Motors

$35.13

0.01 (0.03%)

HMC

Honda

$25.45

0.175 (0.69%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$118.54

1.16 (0.99%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 03

    Jun

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 19

    Jun

  • 19

    Jun

  • 23

    Jun

  • 09

    Jul

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 23

    Oct

  • 27

    Oct

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENC

Fennec

$3.88

(0.00%)

16:36
05/24/19
05/24
16:36
05/24/19
16:36
Conference/Events
Fennec management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 18

    Jun

TD

Toronto-Dominion

$56.66

0.65 (1.16%)

16:35
05/24/19
05/24
16:35
05/24/19
16:35
Syndicate
Breaking Syndicate news story on Toronto-Dominion »

Toronto-Dominion files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
05/24/19
05/24
16:30
05/24/19
16:30
Options
Preliminary option volume of 15.7M today »

Preliminary option volume…

CBUS

Cibus

$0.00

(0.00%)

16:25
05/24/19
05/24
16:25
05/24/19
16:25
Syndicate
Cibus requests withdrawal of registration statement »

The company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$355.14

4.57 (1.30%)

16:23
05/24/19
05/24
16:23
05/24/19
16:23
Periodicals
Boeing 737 MAX return delayed by FAA expanding review, WSJ reports »

A review of Boeing's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

FB

Facebook

$181.03

0.14 (0.08%)

, BA

Boeing

$355.14

4.57 (1.30%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

U.S. stocks, which had a…

FB

Facebook

$181.03

0.14 (0.08%)

BA

Boeing

$355.14

4.57 (1.30%)

UAL

United Continental

$80.77

-0.14 (-0.17%)

SMI

SMIC

$5.23

-0.26 (-4.74%)

HPQ

HP Inc.

$20.03

0.835 (4.35%)

HPE

HP Enterprise

$14.36

0.03 (0.21%)

NVS

Novartis

$87.49

3.03 (3.59%)

CNC

Centene

$56.84

1.39 (2.51%)

WCG

WellCare

$275.45

0.99 (0.36%)

TSS

TSYS

$113.42

13.81 (13.86%)

GPN

Global Payments

$153.42

5.45 (3.68%)

HIBB

Hibbett Sports

$23.91

4.07 (20.51%)

DVAX

Dynavax

$5.77

-0.59 (-9.28%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

SPLK

Splunk

$119.13

-9.55 (-7.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 24

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 08

    Jun

  • 09

    Jun

  • 10

    Jun

  • 13

    Jun

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 09

    Jul

  • 09

    Jul

  • 23

    Jul

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
Options
Closing CBOE SPX and VIX Index summary for May 24th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
05/24/19
05/24
16:17
05/24/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
05/24/19
05/24
16:16
05/24/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHE

Regional Health Properties

$2.06

0.09 (4.57%)

16:15
05/24/19
05/24
16:15
05/24/19
16:15
Hot Stocks
Regional Health Properties receives NYSE notice over late Form 10-Q filing »

Regional Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.